Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Biol Psychiatry. 2011 Sep;12 Suppl 1:89-94. doi: 10.3109/15622975.2011.603229.

Pharmacological treatment of adult ADHD in Europe.

Author information

1
Neurocenter - Saarland University Hospital, Homburg/Saar, Germany. wolfgang.retz@uks.eu

Abstract

OBJECTIVES:

It is now widely accepted that ADHD is a frequent chronic condition with a lifelong perspective. Adult ADHD is a reliable and valid diagnosis. The disorder and the co-morbid conditions can place a severe burden on the patients, their families and their partners, requiring adequate treatment.

METHODS:

A systematic literature search was conducted to review the available pharmacological treatment options for adults with ADHD in European countries.

RESULTS:

Supported by meta-analyses, stimulant medication is the first-line pharmacological therapy for adult ADHD. However, from a European perspective the pharmacological treatment options are very limited and only a minority of adults with ADHD in European countries receives adequate treatment.

CONCLUSIONS:

With reference to the epidemiological data, it seems very likely that the number of people with ADHD in Europe seeking multimodal treatment including pharmacotherapy, psychotherapy, coaching or other therapeutic services will increase profoundly during the coming years.

PMID:
21906003
DOI:
10.3109/15622975.2011.603229
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center